Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Leukemia, acute myeloid (AML), child
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 185 for your search:
Start Over
Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 21 and under
Sponsor: Other
Protocol IDs: TASMC-11-MB-442-CTIL, NCT01339988
Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes
Phase: Phase IV
Type: Treatment
Status: Active
Age: 10 to 90
Sponsor: Other
Protocol IDs: MST/MDS-307PLAH-ASH, NCT01674985
Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT
Phase: Phase IV
Type: Treatment
Status: Active
Age: 65 and younger
Sponsor: Other
Protocol IDs: PUPH IRB [2013](38), NCT02027064
Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: BfArM 4022064, DKH 50-2728, UCHM-AML-BFM-2004, UCHM-BfArM 4022064, UCHM-DKH 50-2728, EU-20723, AML-BFM 2004, NCT00111345
Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: IAPLSG2004, BT/PR4460/Med/14/531/2003, NCT00517712
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: MT2006-13, 0607M89052, UMN-MT2006-13, NCT00630565
Low-energy Laser Therapy for Prevention of Oral Mucositis in Children
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: 0 to 18
Sponsor: Other
Protocol IDs: CHU-0060, NCT01007617
Unrelated Double Umbilical Cord Blood Units Transplantation
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 1 to 50
Sponsor: Other
Protocol IDs: HORCSCT-0902, NCT01015742
Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 16 to 80
Sponsor: Other
Protocol IDs: CHG-DAC 001, SHDC12010202, NCT01417767
Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: Busulfan-2013, NCT01800643
Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: P030441, AOM 03142, NCT00149162
Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML
Phase: Phase III
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: AML SCT-BFM 2007, 2007-004517-34, NCT00606723
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
Phase: Phase III
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SCT 0307, NCT00619879
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI, Other
Protocol IDs: AML08, 5R01CA138744, 1R01CA115422, NCT00703820
A Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in the Young With Acute Leukemia Remission
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: Under 35
Sponsor: Other
Protocol IDs: 2009-17, 2009-A00792-55, NCT01067300
Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: ICC APL STUDY 01, NCT01226303
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: NCI-2011-02670, COG-AAML1031, CDR0000701850, AAML1031, U10CA180886, U10CA098543, NCT01371981
PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: PRO#1278: Flu-Bu-TBI, NCT01366612
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase: Phase III
Type: Treatment
Status: Active
Age: 3 to 70
Sponsor: Other
Protocol IDs: 2011-0628, NCI-2012-00038, NCT01471444
HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 7 to 60
Sponsor: Other
Protocol IDs: MST-AML-307PLAH-ASH, NCT01484171
Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: AML HIDAC, AIIMS, NCT01615757
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 15 to 60
Sponsor: NCI
Protocol IDs: NCI-2013-00490, PS1203_A06PAMDREVW01, SWOG-S1203, S1203, U10CA180888, U10CA032102, NCT01802333
Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 19
Sponsor: Other
Protocol IDs: NOPHO-DBH-AML2012, 2012-002934-35, NCT01828489
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Phase: Phase III
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: CB-AB006, 2012-0166, NCT01854567
Start Over